0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Small Case Series |

Fungal Endophthalmitis Developing in Asthmatic Individuals Treated With Inhaled Corticosteroids FREE

Vera A. Mayercik, AB; Andrew W. Eller, MD; Matthew S. Pihlblad, MD
[+] Author Affiliations

Author Affiliations: Department of Ophthalmology, University of Pittsburgh Medical Center Eye Center, Eye and Ear Institute (Drs Eller and Pihlblad), University of Pittsburgh School of Medicine (Ms Mayercik), Pittsburgh, Pennsylvania.


Arch Ophthalmol. 2011;129(7):952-953. doi:10.1001/archophthalmol.2011.184.
Text Size: A A A
Published online

Candida albicans is a normal component of human microbial flora of the skin and gastrointestinal tract. When it gains access to the bloodstream, resulting in fungemia, susceptible patients may develop endogenous fungal endophthalmitis (EFE). A number of risk factors have been associated with Candida endophthalmitis and are shown in the Table. These include long-term intravenous therapy, intravenous drug abuse, and even lithotripsy.1,2 In this article, we propose another risk factor for EFE—the use of inhaled corticosteroids in the treatment of asthma.

Table Graphic Jump LocationTable. Risk Factors for Endogenous Fungal Endophthalmitis

Oral candidiasis secondary to the treatment of asthma with inhaled corticosteroids has been well-documented in the medical literature.3 We hypothesize that oral candidiasis may cause transient fungemia, which can seed the choroid and lead to EFE.

Case 1

The patient was a 68-year-old woman with a history of asthma and decreased, “cloudy” vision in both eyes for a period of 2 days. She had recently experienced an asthma exacerbation treated with inhaled corticosteroids and subsequently developed oral candidiasis treated with local application of nystatin.

Examination revealed a visual acuity of counting fingers at 1 foot in both eyes, 1+ conjunctival injection, and 4+ cell in the anterior chamber with 1-mm hypopyon and posterior synechiae bilaterally (Figure). The anterior vitreous of the right eye was poorly visualized owing to a small pupil, while the left eye revealed vitreous cells. The media was hazy, and vitreous debris was seen on B-scan bilaterally.

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Case 1 slitlamp photograph of the right eye demonstrating 1+ conjunctival injection, 1-mm hypopyon, and posterior synechiae.

A clinical diagnosis of bilateral EFE was made, and she was treated with 200 mg of oral fluconazole twice daily for 1 month. In addition, she was given topical corticosteroids and cycloplegic eye drops. At the 1-month follow-up, her visual acuity was 20/25 in both eyes. As a result of fluconazole treatment, the patient resolved her infection and experienced a significant improvement in visual acuity, confirming our clinical diagnosis.

Case 2

The patient was a 67-year-old woman with a history of steroid-dependent asthma and chronic obstructive pulmonary disease who presented with 2 days of decreased visual acuity in the left eye and retro-orbital and facial pain. In the 2 months prior, she had 3 hospital admissions for asthma exacerbations that were treated with inhaled corticosteroids. During these episodes, she developed oral candidiasis treated locally with nystatin.

The patient's left eye had a visual acuity of counting fingers at 6 inches, 2+ conjunctival injection, 4+ cell and flare in the anterior chamber with 0.5 mm hypopyon, 3+ anterior vitreous cells, hazy fundus view with dull red reflex, and a “chalky white” lesion in the posterior pole. She was diagnosed clinically with EFE and treated with an intravitreal injection of 5 μg/0.1 mL of amphotericin B as well as corticosteroid and cycloplegic eye drops.

At the 2-week follow-up, the patient had decreased vision and increased pain in the left eye. Examination revealed a large, tender posterior cervical lymph node on the right side, and she appeared systemically ill. The patient was admitted for evaluation for systemic fungal infection and taken to the operating room for pars plana vitrectomy and another intravitreal amphotericin B injection. During surgery, she was found to have a white fluffy vitreous abscess attached to the retina just above the supratemporal arcade; however, results of vitreous culture testing were negative for C albicans. She was treated with 400 mg of amphotericin B lipid complex every other day, 200 mg of oral fluconazole every other day, topical corticosteroids, and cycloplegic eye drops for 5 weeks.

Two months later, the patient's visual acuity was 20/50 in the affected eye, with mild vitreous debris in the left eye. The initial intravitreal antifungal injection was unsuccessful; however, systemic antifungal treatment was able to resolve the ocular and presumed systemic infection.

Endogenous fungal endophthalmitis can be difficult to diagnose. It should be suspected in any patient who presents with decreased vision or mild anterior uveitis, with or without hypopyon and one of the risk factors listed in the Table. A positive result on vitreous culture testing serves as the criterion standard for diagnosis, while testing of cultures from blood or urine can support the diagnosis without an invasive eye procedure. Even when vitrectomy is performed, growth on culture media has been reported at only 47%, so diagnosis is often made clinically and supported by response to empirical antifungal treatment.4 In our experience, cultures must include the abscess to test positive for C albicans. Polymerase chain reaction also has the capability to detect C albicans ; however, it is not widely available at this time.

Here we describe 2 asthmatic patients who use inhaled corticosteroids who developed oral candidiasis that was treated locally with nystatin only and were diagnosed clinically with EFE. We propose that a careful medical history should include not only the typical risk factors listed in the Table but also the additional risk factors of asthma, inhaled corticosteroids, and oral candidiasis highlighted in these cases. We hypothesize that the pathogenesis of the EFE in these cases originated from oral candidiasis due to inhaled corticosteroids used in the treatment of asthma, a well-established phenomenon.4

Another clinical point derived from these cases is that local treatment with intravitreal amphotericin B may not be sufficient, as patients are at risk for the development of a systemic infection that requires treatment as well, as in case 2. Systemic treatment with oral fluconazole has been shown to be effective, as in case 1, with or without vitrectomy and intravitreal amphotericin B, depending on vitreal involvement.5 In the cases presented here, resolution of infection occurred with treatment with systemic antifungals. These cases demonstrate another underlying etiology of fungal endophthalmitis that should be added to the list of risk factors.

Correspondence: Dr Eller, Department of Ophthalmology, Eye and Ear Institute, UPMC Eye Center, University of Pittsburgh School of Medicine, 203 Lothrop St, Pittsburgh, PA 15213 (elleraw@upmc.edu).

Financial Disclosure: None reported.

Essman TF, Flynn HW Jr, Smiddy WE,  et al.  Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis.  Ophthalmic Surg Lasers. 1997;28(3):185-194
PubMed
Samiy N, D’Amico DJ. Endogenous fungal endophthalmitis.  Int Ophthalmol Clin. 1996;36(3):147-162
PubMed   |  Link to Article
Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma.  Allergy. 2006;61(5):518-526
PubMed   |  Link to Article
Margolis R, Brasil OF, Lowder CY,  et al.  Vitrectomy for the diagnosis and management of uveitis of unknown cause.  Ophthalmology. 2007;114(10):1893-1897
PubMed   |  Link to Article
Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis.  Clin Infect Dis. 1995;20(3):657-664
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Case 1 slitlamp photograph of the right eye demonstrating 1+ conjunctival injection, 1-mm hypopyon, and posterior synechiae.

Tables

Table Graphic Jump LocationTable. Risk Factors for Endogenous Fungal Endophthalmitis

References

Essman TF, Flynn HW Jr, Smiddy WE,  et al.  Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis.  Ophthalmic Surg Lasers. 1997;28(3):185-194
PubMed
Samiy N, D’Amico DJ. Endogenous fungal endophthalmitis.  Int Ophthalmol Clin. 1996;36(3):147-162
PubMed   |  Link to Article
Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma.  Allergy. 2006;61(5):518-526
PubMed   |  Link to Article
Margolis R, Brasil OF, Lowder CY,  et al.  Vitrectomy for the diagnosis and management of uveitis of unknown cause.  Ophthalmology. 2007;114(10):1893-1897
PubMed   |  Link to Article
Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis.  Clin Infect Dis. 1995;20(3):657-664
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario